In an interview about the efficacy of COVID-19 vaccines, Richard Marlink, the director of Rutgers Global Health Institute, responds to public opinion about the differences among vaccines that are authorized or in the pipeline for use in the United States. The following is an excerpt from the story published by ROI-NJ: When the news that Johnson & Johnson had completed Phase 3 of its clinical trial and that its one-shot vaccine would soon be available finally was released Friday morning, there was unbridled excitement. It would be a game-changer, many said. To read the full story.
Recent Posts
- Researchers Examine the Persistence of Invisible Plastic Pollution.
- Rutgers Health Officials Celebrate $47.5 Million Grant to Improve Health Care in New Jersey.
- NJACTS Community Engagement Core Available Services
- New Model Identifies Best Candidates for Epilepsy Surgery.
- Study Finds Telehealth Effective for HIV Patients.
Categories
- Community (2,050)
- Covid (978)
- CTO Events (4)
- News (2,604)
- Pilots (20)